Why We Give Cryoprecipitate
Cryoprecipitate is administered primarily to rapidly replace fibrinogen in bleeding patients with hypofibrinogenemia, particularly during major hemorrhage, massive transfusion, and obstetric emergencies. 1
What Cryoprecipitate Contains
Cryoprecipitate is a concentrated plasma product derived from fresh frozen plasma that contains:
- Fibrinogen (400-450 mg per single unit; pooled units of 5 contain at least 2 g)
- Factor VIII
- von Willebrand factor
- Factor XIII
- Fibronectin 1
This concentrated fibrinogen content makes it the most efficient blood product for correcting hypofibrinogenemia during active bleeding.
Primary Clinical Indications
Major Hemorrhage and Massive Transfusion
The most common and evidence-supported indication is hypofibrinogenemia during major bleeding, particularly in:
- Trauma patients with massive transfusion requirements
- Obstetric hemorrhage (maintain fibrinogen >2.0 g/L)
- Cardiac surgical bleeding
- Other major hemorrhage (maintain fibrinogen >1.5 g/L) 1
Recent trauma data demonstrates that high cryoprecipitate ratios (≥1:1 cryoprecipitate to RBC) are independently associated with decreased mortality at 6 and 24 hours, with optimal dosing appearing to be approximately 1 pooled unit per 7-8 units of RBCs 2, 3.
Specific Coagulopathic States
Cryoprecipitate is indicated when fibrinogen levels fall below critical thresholds:
- Disseminated intravascular coagulation (DIC) with fibrinogen <1.0 g/L 1
- Combined liver and renal failure with active bleeding 1
- Bleeding associated with thrombolytic therapy 1
- Advanced liver disease to maintain fibrinogen >1.0 g/L 1
When Laboratory Testing is Unavailable
As an adjunct in massively transfused patients when fibrinogen concentrations cannot be measured in a timely fashion 4. This recognizes the reality that during life-threatening hemorrhage, waiting for laboratory results may be inappropriate.
Congenital Fibrinogen Deficiencies
For patients with inherited fibrinogen disorders, though specific factor concentrates are preferred when available 4.
Von Willebrand Disease
When specific VWF/FVIII concentrate is unavailable or ineffective, cryoprecipitate serves as an alternative source of von Willebrand factor 4.
Dosing Strategy
Standard adult dose: 2 pools (10 units total) administered through a standard blood giving set with 170-200 μm filter 1
The initial fibrinogen supplementation should be 3-4 g, equivalent to 15-20 single donor units of cryoprecipitate. Repeat doses should be guided by viscoelastic monitoring and laboratory fibrinogen levels 5.
Critical Fibrinogen Thresholds
The guidelines establish clear transfusion triggers based on clinical context:
- General major hemorrhage: Maintain fibrinogen >1.5 g/L 1
- Active obstetric hemorrhage: Maintain fibrinogen >2.0 g/L 1
- DIC with bleeding: Transfuse when <1.0 g/L 1
- Excessive bleeding: Usually indicated when <80-100 mg/dL 4
- Rarely indicated: When fibrinogen >150 mg/dL in non-pregnant patients 4
Evidence of Effectiveness
Cryoprecipitate effectively raises fibrinogen levels with a mean increase of approximately 0.71 g/L per dose 6. The effect is most pronounced in patients with the most severe bleeding (≥10,000 mL blood loss), where approximately 70% of patients with fibrinogen <150 mg/dL improved to ≥150 mg/dL after administration 7.
In massively transfused trauma patients, adjunctive cryoprecipitate use was associated with reduced mortality (OR 0.78 for 24-hour mortality, OR 0.79 for in-hospital mortality) without increasing complications 8. The 2019 Joint Trauma System guideline recommending empiric 1:1 cryoprecipitate to RBC ratios appears supported by subsequent data showing protective effects at high ratios 2.
Practical Considerations
Storage and Administration
- Stored at -25°C
- Once thawed, can be kept at ambient temperature for 4 hours maximum
- Should not be refrigerated after thawing 1
Cryoprecipitate vs. Fibrinogen Concentrate
While fibrinogen concentrate may offer logistical advantages (easier storage and reconstitution), cryoprecipitate remains the standard of care in many settings, particularly where fibrinogen concentrate is unavailable 9, 10. Recent evidence suggests similar outcomes between the two products in cardiac surgery-related bleeding 9.
Common Pitfalls to Avoid
Do not wait for laboratory confirmation during life-threatening hemorrhage—empiric administration is appropriate in massive transfusion scenarios 4
Do not underdose—inadequate cryoprecipitate ratios (>8:1 RBC:Cryo) fail to provide survival benefit 3
Do not use for volume replacement—cryoprecipitate is specifically for fibrinogen/factor replacement, not circulatory volume 1
Do not forget obstetric patients require higher targets—maintain fibrinogen >2.0 g/L rather than the standard >1.5 g/L 1, 4
Do not refrigerate after thawing—this damages the product; use within 4 hours or discard 1